Last reviewed · How we verify
NCT06016283
Sex Impact on Long-term Outcomes of LDKT
trial in Kidney Transplant Failure and Rejection in 1,276 participants. Completed in 30 November 2024.
30 October 2024
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,276 |
| Start date | 1 April 2022 |
| Primary completion | 30 October 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across Netherlands |
Conditions studied
- Kidney Transplant Failure and Rejection — all drugs for Kidney Transplant Failure and Rejection →
- Gender — all drugs for Gender →
Sponsor
Erasmus Medical Center
Who can join
18 and older, any sex, with Kidney Transplant Failure and Rejection or Gender. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The impact of donor and recipient gender combination on kidney transplant outcomes has been reported in several studies. The results vary greatly due to different factors, such as minor histocompatibility antigens, nephron overload, sex hormones, etc. Despite advancements in clinical practice, no large-scale studies exploring this question in living donor kidney transplantation have been conducted in the subsequent two decades. Our study aims to address this research gap and provide updated information on outcomes in relation to the gender combination following living donor kidney transplantation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of Donor and Recipient Sex on Long-Term Outcomes Following Living Donor Kidney Transplantation: A Retrospective Dual-Center Study.
Fang Y, Westenberg LB, Hamm JJM, van de Wetering J, et al · · 2025 · PMID 41020661 · DOI 10.1111/ctr.70335
Verify or expand the search:
- PubMed search for NCT06016283
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Failure and Rejection
Currently open trials in the same condition.
- NCT05325008 — A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients · Phase 3 · recruiting
- NCT03955172 — Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated · NA · recruiting
- NCT04526431 — Tacrolimus Pharmacokinetic Subpopulations · recruiting
- NCT04369612 — Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples · NA · recruiting
- NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06016283 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06016283.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing